Bright Minds Biosciences to Present at Upcoming Conferences
Rhea-AI Summary
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in four upcoming conferences in August and September 2025.
The conferences include the 36th International Epilepsy Congress in Lisbon (Aug 30-Sep 3), Cantor Global Healthcare Conference (Sep 5), H.C. Wainwright Global Investment Conference (Sep 9), and Baird Global Healthcare Conference (Sep 10). A live webcast will be available for the Cantor event through the company's investor relations website, with replay accessible for 60 days.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, DRUG declined 5.14%, reflecting a notable negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $17M from the company's valuation, bringing the market cap to $317M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
| EVENT: | 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, Portugal |
| DATE: | August 30 – September 3, 2025 |
| EVENT: | Cantor Global Healthcare Conference 2025 |
| DATE: | Friday, September 5, 2025 |
| TIME: | 9:45am ET |
| WEBCAST: | https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=37737154 |
| EVENT: | H.C. Wainwright 27th Annual Global Investment Conference |
| DATE: | Tuesday, September 9, 2025 |
| TIME: | 3:00pm ET |
| WEBCAST: | There is no webcast for this event |
| EVENT: | Baird 2025 Global Healthcare Conference |
| DATE: | Wednesday, September 10, 2025 |
| TIME: | 9:05am ET |
| WEBCAST: | There is no webcast for this event |
The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
FAQ
When is Bright Minds Biosciences (NASDAQ: DRUG) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Bright Minds Biosciences' presentation at the Cantor Conference?
What therapeutic areas is Bright Minds Biosciences (DRUG) focusing on?
Which conferences will Bright Minds Biosciences attend in September 2025?
